valrubicin has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baby, K; Maity, S; Mehta, CH; Nayak, UY; Nayak, Y; Suresh, A | 1 |
1 other study(ies) available for valrubicin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
Topics: Angiotensin-Converting Enzyme 2; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Doxorubicin; Drug Repositioning; Enzyme Inhibitors; Humans; Lopinavir; Molecular Docking Simulation; Molecular Dynamics Simulation; SARS-CoV-2; Serine Endopeptidases; Topoisomerase II Inhibitors; Virus Internalization | 2021 |